5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.75▼ | 3.75▼ | 3.75▼ | 3.75▼ | 3.81▼ |
MA10 | 3.81▼ | 3.79▼ | 3.76▼ | 3.77▼ | 5.33▼ |
MA20 | 3.88▼ | 3.87▼ | 3.85▼ | 3.85▼ | 6.53▼ |
MA50 | 3.96▼ | 4.20▼ | 4.43▼ | 5.72▼ | 11.68▼ |
MA100 | 4.85▼ | 5.43▼ | 5.86▼ | 6.69▼ | 20.09▼ |
MA200 | 6.66▼ | 7.29▼ | 7.10▼ | 10.31▼ | 52.25▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.009▼ | 0.016▲ | 0.036▲ | 0.118▲ | -0.025▼ |
RSI | 41.442▼ | 41.229▼ | 38.760▼ | 34.207▼ | 28.213▼ |
STOCH | 29.327 | 28.966 | 28.966 | 32.322 | 2.921▼ |
WILL %R | -72.414 | -72.414 | -72.414 | -68.571 | -98.126▼ |
CCI | -60.087 | -59.078 | -57.598 | -77.496 | -89.906 |
MA | $NCNA Price Crossed Below MA(7) | Set Alert |
Thursday, May 16, 2024 01:22 PM
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Canc ...
|
Thursday, May 16, 2024 01:01 PM
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging ...
|
Thursday, May 16, 2024 09:02 AM
EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/05/24 | 3.74 | 3.74 | 3.70 | 3.70 | 11,764 |
15/05/24 | 3.852 | 3.9799 | 3.77 | 3.78 | 24,966 |
14/05/24 | 3.68 | 3.88 | 3.68 | 3.88 | 14,231 |
13/05/24 | 3.80 | 3.80 | 3.80 | 3.80 | 17,123 |
10/05/24 | 3.52 | 3.62 | 3.41 | 3.59 | 17,918 |
09/05/24 | 3.606 | 3.8099 | 3.4067 | 3.50 | 35,364 |
08/05/24 | 4.01 | 4.3399 | 3.53 | 3.67 | 329,023 |
07/05/24 | 3.87 | 4.01 | 3.87 | 3.91 | 5,505 |
06/05/24 | 4.00 | 4.00 | 3.85 | 3.88 | 31,493 |
03/05/24 | 3.91 | 4.178 | 3.89 | 4.00 | 28,655 |
|
|
||||
|
|
||||
|
|